About

Company Overview

Founded in 2004 in Oceanside, California, Kinovate Life Sciences is a wholly owned subsidiary of Nitto Denko Corporation, a global Japanese industrial leader headquartered in Osaka,Japan. Kinovate was established as a spin-off from Nitto Denko Technical Corporation to focus exclusively on advanced material for life science applications.

Since its inception, the company has evolved into a market leader in solid supports for oligonucleotide synthesis, recognized for consistent product performance, responsive customer service, and competitive cost structures. In 2026, Kinovate expanded its U.S. footprint by relocating to a new, state-of-the-art manufacturing facility in Carlsbad, California, supporting continued growth and enhanced operational capabilities.

Kinovate’s success is driven by the combination of Nitto’s deep materials science heritage and Kinovate’s specialized expertise in life sciences. The company offers comprehensive capabilities across manufacturing, analytical development, quality control, and technical customer support. Backed by a dedicated and highly experienced team, Kinovateis committed to delivering high-quality products and dependable service to support critical applications across the life sciences industry.

Watch the Video

Environment Health & Safety

We place safety before everything else

Zero CO2 Emissions

No natural gas used for heating or cooling, and increased reliance on renewable energy sources to cancel out carbon footprint at our new facility scheduled to begin operations in 2026.

Minimize Environmental Impact

New closed solvent system design allows for future solvent and chemical reuse and recycling.

Secure Production

Separate storage areas for raw materials & finished products, and secure transfer rooms & pass-through windows to safely move materials.

Responsible Scalability

Expanded 2,750 sqft capacity in upgraded facility to meet surging demand with eco-friendly solutions.

Environmental, Social & Governance (ESG)

Ongoing training for staff, EHS programs & contingency planning to ensure compliance with industry standards and business continuity.

Quality Assurance

Our state-of-the-art manufacturing facilities, talented team and stringent Quality Control and analysis capabilities are unmatched. Kinovate manufactures NittoPhase™ products under ISO 9001:2015 guidelines and provides all the required documentation for customers to file with regulatory bodies when needed.

Supply Security

With a “business continuity plan” in place and supported by Osaka, Japan based Nitto Denko Group, Kinovate is backed by formidable resources. We know “supply security” is important to therapeutic programs. Trust us, we have your back.

Customer Service

At Kinovate, we are committed to providing exceptional support at every stage of your program, whether you are in discovery, preclinical development, clinical trials, or post-approval production. From technical guidanceto documentation support, our team is ready to assist with your needs. No matter the request, we’re here to help you move forward with confidence.

Products

Kinovate offers solid support loaded with deoxy-, ribo-, 2’-methoxy- and 2’-Fluoro-nucleosides at loading range from 40 to 400 µmol/g. We also offer various non-nucleoside linkers and ligands attached to the NittoPhase™ product line. Popular products of ours, manufactured under license include the NittoPhase™ HL UnyLinker™ at 40 to 400 µmol/g. We also offer “custom” loading of your choice of novel ligand(s) at small to large scales at competitive cost for customers to explore and to optimize their oligo synthesis strategies.

The NittoPhase™ product family deliver scalable, consistent, and unparalleled synthesis performance with exceptional quality for DNA, RNA and modified oligos at loadings ranging from 40 to 400 µmol/g. Kinovate’s solid supports have yielded superb results in syntheses of oligonucleotide for clinical studies from micromole to over 900 millimole scales.

Explore Products

Nitto Denko Corp

Founded in 1918 to produce electrical insulation materials for Japan’s developing industries, Nitto has grown from its early roots in materials manufacturing to a global leader in advanced materials. Today, Nitto develops and delivers a broad range of high-performance products—including tapes, films, membranes, and medical solutions—supported by strong core technologies and a commitment to customer-oriented innovation.

For more than a century, the Nitto Group has continuously created value by integrating proprietary technologies and applying them across diverse industries. By anticipating societal needs and adapting to changing markets, Nitto has expanded its business domains while maintaining a consistent focus on technical excellence, sustainable growth, and solutions that contribute to customer’s success.

1918

Established on October 25, 1918.

1960s

Breaking new ground by accelerating business diversification and expanding operations overseas.

2000s

Revamped the business portfolio to deliver better customer service and proactively anticipate change.

1950s

The Nitto Group’s unique marketing approach began, marked by the launch of innovative sales and promotional activities.

1990s

Initiated the Global Niche Top™ strategy, focusing on leadership in highly specialized markets.

2020s

Placing ESG at the core of management to enhance long-term corporate value.